Cognitive impairments in Alzheimer's disease (AD) have been associated with alterations in
neuronal oscillatory activity, of which hippocampal theta and gamma oscillations are …

The 5-HT 6 receptor has emerged as a promising target for cognitive disorders and
combining a 5-HT 6 receptor antagonist with an acetylcholinesterase inhibitor (AChEI) …

The 5-HT 6 receptor is a promising target for cognitive disorders, in particular for Alzheimer's
disease (AD). The high affinity and selective 5-HT 6 receptor antagonist idalopirdine (Lu …

One of the major neuropathological hallmarks in Alzheimer's disease (AD) is the loss of
cholinergic neurones of the nucleus basalis of Meynert (NbM). This consistent finding gave …

Background The 5-HT6 receptor is primarily localized in the brain, in areas relevant for
cognition. Combining a 5-HT6 receptor antagonist and an acetylcholinesterase inhibitor …

Antagonism of the 5-HT 6 receptor is a promising approach for the symptomatic treatment of
Alzheimer's disease (AD). There is compelling preclinical evidence for the procognitive …

5-Hydroxytryptamine (5-HT) 4 receptor agonists reportedly stimulate brain acetylcholine
(ACh) release, a property that might provide a new pharmacological approach for treating …

Systemic administration of the muscarinic-receptor antagonists atropine and scopolamine
produces cognitive deficits in humans, nonhuman primates and rodents. In humans, these …

Abstract Background Translational research in Alzheimer's disease (AD) pathology provides
evidence that accumulation of amyloid-β and hyperphosphorylated tau, neuropathological …

Considerable evidence indicates that both cholinergic (ACh) and serotonergic (5-HT) inputs
to the neocortex play a direct role in maintaining the activated state of the …